My son has a terminal disease — why FDA delays are failing families like mine
Angelina Olivera, a mother and caregiver to her 14-year-old son Ryu who has Duchenne muscular dystrophy, criticizes the FDA for delays in approving experimental treatments that could save lives. She argues that bureaucratic caution is prioritized over urgent patient needs, especially for rare disease communities with limited financial resources. The departure of FDA biologics director Dr. Vinay Prasad presents an opportunity for reform, she says, urging Commissioner Dr. Martin Makary to appoint a successor who values patient access and regulatory flexibility.
- ▪Angelina Olivera's son Ryu has Duchenne muscular dystrophy, a terminal illness that also killed her two brothers.
- ▪Ryu's monthly steroid treatment costs $30,000, with significant out-of-pocket expenses despite insurance and nonprofit assistance.
- ▪FDA review delays and restricted access to therapies have frustrated rare disease families, who feel the agency prioritizes caution over urgent patient needs.
- ▪Dr. Vinay Prasad, FDA’s biologics director, is departing, creating an opening for leadership change in treatment approval processes.
- ▪Olivera urges FDA Commissioner Dr. Martin Makary to appoint a new director who supports regulatory flexibility and patient access to experimental drugs.
Fox News — Latest files mainly under news. We currently carry 3,554 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Fox News — Latest |
| Canonical URL | https://www.foxnews.com/opinion/son-terminal-disease-fda-delays-failing-families-like-mine |
| Publication time | Wed, 29 Apr 2026 05:00:34 -0400 |
| Retrieval time | 2026-04-29T09:06:54.500Z |
| Last seen | 2026-04-29T09:06:54.500Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | zicPlUkEplS2 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Opinion My son has a terminal disease — why FDA delays are failing families like mine The departure of FDA biologics director Vinay Prasad creates an opportunity for a reset By Angelina Olivera Fox News Published April 29, 2026 5:00am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Dr. Marty Makary on estrogen patch shortages and FDA's role FDA Commissioner Dr. Marty Makary discusses the demand surge and shortages of estrogen patches. He explains the FDA's decision to remove the black box warning, leading to increased demand, and its impact on women's health and menopause.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News — Latest.
Discussion
0 commentsMore from Fox News — Latest
